Drugs / Pecavaptan
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05599997 | Nov 2019 → Jan 2021 | congestive heart failure, impaired renal function disease | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03901729 | May 2019 → Apr 2021 | heart failure | Bayer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pecavaptan | “A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure:...” PMID 40788619 ↗ Aug 2025 |
| Known as | BAY1753011 | “Pecavaptan (BAY1753011)” NCT05599997 ↗ |
| Action | Inhibit | “pecavaptan, a novel, balanced dual-acting V1a/V2 vasopressin antagonist” PMID 33188886 ↗ Oct 20202“Vasopressin V1a receptor antagonist” CHEMBL4594444 ↗ “Vasopressin V2 receptor antagonist” CHEMBL4594444 ↗ |
| Modality | Small molecule | — CHEMBL4594444 ↗ |
| Route | Oral | “Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral” NCT03901729 ↗ |
| Target | AVPR1A | “Vasopressin V1a receptor antagonist” CHEMBL4594444 ↗ |
| Target | AVPR2 | “Vasopressin V2 receptor antagonist” CHEMBL4594444 ↗ |